Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

KINLYTIC

UROKINASE

Standard Dose
5,000 IU/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview KINLYTIC is listed in Drugs@FDA under application 021846 (BLA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient UROKINASE Form and strength INJECTABLE;INJECTION - 5,000 IU/VIAL Sponsor MICROBIX BIOSYSTEMS Submission history Latest submission status date: 2008-07-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview KINLYTIC is listed in Drugs@FDA under application 021846 (BLA). Review priority: STANDARD Marketing status: Discontinued Active ingredient UROKINASE Form and strength INJECTABLE;INJECTION - 5,000 IU/VIAL Sponsor MICROBIX BIOSYSTEMS Submission history Latest submission status date: 2008-07-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.